ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Incidence, Determinants and Outcome of Kidney Transplantation for End Stage Renal Disease After Heart Transplantation

A. Grupper,1 A. Grupper,1 R. Daly,1 M. Hathcock,2 W. Kremers,2 F. Cosio,1 B. Edwards,1 S. Kushwaha.1

1William J. von Liebig Transplant Center, Mayo Clinic, Rochester, MN
2Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.

Meeting: 2015 American Transplant Congress

Abstract number: B5

Keywords: Calcineurin, Heart transplant patients, Kidney transplantation, Renal failure

Session Information

Date: Sunday, May 3, 2015

Session Name: Poster Session B: "A Descent into the Maelstrom": Complications After Heart Transplantation

Session Time: 5:30pm-6:30pm

 Presentation Time: 5:30pm-6:30pm

Location: Exhibit Hall E

Related Abstracts
  • Risk of End-Stage Renal Disease After Living Donor Liver Transplantation: Overall Incidence and Comparisons to Deceased Donor Recipients
  • Outcomes of Live Kidney Donors Who Develop End Stage Renal Disease

Objectives: Progressive renal failure is a frequent complication following heart transplantation (HTx), is generally attributed to calcineurin inhibitor (CNI) based immunosuppression, and may result in end stage renal disease (ESRD) prompting consideration of kidney after heart transplantation (KAH). The aim of this study was to: (a) determine the incidence and identify risk factors for the development of ESRD post HTx, (b) to assess long-term renal graft survival in KAH recipients and (c) to evaluate survival benefit of KAH.

Methods: We identified 268 (mean age 50 ± 12 years) patients who underwent HTx or KAH between the years 2000-2012. GFR was measured as corrected iothalamate clearance and ESRD defined as the need for renal replacement therapy.

Results: During a median follow up time of 76 months (42, 121) 51 patients (19%) developed ESRD. The mean time from HTx to ESRD was 83 months (40, 116). Recipients who developed ESRD had significantly lower GFR at HTx, higher incidence of dilated cardiomyopathy and diabetes mellitus post-HTx compared to patients without ESRD (p<0.05). The incidence of switching to a CNI free regimen (sirolimus as primary immunosuppression) was significantly lower among recipients with ESRD (6 vs. 57%, p=0.0001), and prolonged exposure to CNI significantly increased the risk for ESRD (HR=1.09, 1.03 to 1.15, p<0.005). Among recipients with ESRD, 39 patients (76%) underwent KAH during follow up period. The median time from HTx to KAH was 103 months (56, 144). Death censored renal graft survival post KAH was 95%, 95% and 83% at 1, 5 and 10 years, respectively. Long term survival of KAH patients was comparable to HTx recipients without ESRD (median survival time 16 years) and significantly better compared to HTx recipients with ESRD (p<0.001).

Conclusion: Prolonged exposure to CNI immunosuppression medications significantly increases the risk for ESRD among HTx recipients. KAH is a good therapeutic option with comparable survival benefit to HTx alone and good long term renal allograft function.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Grupper A, Grupper A, Daly R, Hathcock M, Kremers W, Cosio F, Edwards B, Kushwaha S. Incidence, Determinants and Outcome of Kidney Transplantation for End Stage Renal Disease After Heart Transplantation [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/incidence-determinants-and-outcome-of-kidney-transplantation-for-end-stage-renal-disease-after-heart-transplantation/. Accessed April 15, 2021.

« Back to 2015 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Home
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Home
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.